We are AliveDx.
In-Vitro Diagnostic Products & Solutions
At AliveDx, we empower diagnostic insights to transform patient care and innovate for life. With over 30 years of experience in in-vitro diagnostics, we advance global testing in autoimmune, allergy and related clinical fields. Our products and solutions: Alba, MosaiQ and LumiQ deliver clinical and economic value by simplifying and improving lab workflow efficiency. Through innovation and reliability, we help healthcare professionals deliver accurate results that enhance patient care.
A Drive to Provide Solutions
With over 30 years of experience in immunohematology and in-vitro diagnostics, our products and solutions address today’s challenges in clinical and laboratory environments. We are committed to meeting the global needs of patients and clinicians.
MosaiQ®
Our MosaiQ solution is designed to shorten time-to-diagnosis for patients by providing faster in-vitro test results. As an easy-to-use single solution, the platform performs multiple tests and gives maximum flexibility to laboratorians and clinicians.
LumiQ®
All-in-one Immunofluorescence (IFA) solution – the LumiQ system is designed to provide workflow efficiency from patient sample in, to result out
Alba
The Alba manual reagent product line is backed by expert technical support and reliable customer service. Join our satisfied customers and see the difference that Alba can make in your laboratory.
Trending Topics
Recent press, briefings and insights helping you stay informed on AliveDx news.
-
AliveDx featured in The Guardian newspaper as one of the UK’s Best Workplaces in Biopharma
Following our recent announcement that AliveDx had been shortlisted, we’re proud to confirm that we’ve now been officially recognised as one of the UK’s Best Workplaces in Biopharma with the list now published in The Guardian. This recognition places AliveDx
-
AliveDx named one of the UK’s Best Workplaces in BioPharma™ 2025
We’re proud to announce that AliveDx has been officially recognised as one of the UK’s Best Workplaces in BioPharma™ 2025 by Great Place to Work® UK. This is a prestigious honour that places us among the top 30 biopharma companies
-
AliveDx announces U.S. Food and Drug Administration (FDA) 510(k) submission for its MosaiQ AiPlex® Vasculitis (VAS) assay.
Eysins, Switzerland, September 2nd, 2025 AliveDx, the global in-vitro diagnostics company that aims to transform patient care, today announces that it has submitted 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for the MosaiQ AiPlex® Vasculitis (VAS)
-
AliveDx registers MosaiQ®, its Instrument for Multiplex Testing of Autoimmune Diseases, Allergies and Beyond, as a Class II Exempt Device with the U.S. Food and Drug Administration (FDA)
The MosaiQ instrument is a next-generation, continuous random-access immunoassay platform offering labs automation, simple workflows, fast, multiplexed results and actionable insights for complex-to-diagnose conditions. Eysins, Switzerland – August 25, 2025 – AliveDx, the global in-vitro diagnostics company dedicated to advancing
-
AliveDx Suisse S.A. and Transmedic sign second distribution agreement for Indonesia, Thailand, and Singapore
AliveDx Suisse S.A. (AliveDx) and Transmedic Indonesia, Thailand and Singapore have signed a second distribution agreement, enabling Transmedic to distribute the LumiQ® solution across these markets. The distribution agreement takes effect immediately. This partnership underscores AliveDx’s dedication to expanding its
-
AliveDx Suisse S.A. and Vital Care Production Distribution et Logistique SPA, sign a second distribution agreement for Algeria
AliveDx Suisse S.A. (AliveDx) and Vital Care Production Distribution et Logistique SPA (Vital Care), have signed a second distribution agreement, which will enable Vital Care to distribute the LumiQ® solution in Algeria. The distribution agreement takes effect immediately. This partnership
